221 related articles for article (PubMed ID: 36697062)
1. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
[TBL] [Abstract][Full Text] [Related]
2. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
[TBL] [Abstract][Full Text] [Related]
3. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
[TBL] [Abstract][Full Text] [Related]
4. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
5. [Minimally Invasive Conversion Hepatectomy for Advanced Hepatocellular Carcinoma].
Sakai H; Goto Y; Shimose S; Niizeki T; Kawaguchi T; Akiba J; Yano H; Akagi Y; Fujita F; Hisaka T
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1572-1574. PubMed ID: 38303345
[TBL] [Abstract][Full Text] [Related]
6. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
7. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
8. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
[TBL] [Abstract][Full Text] [Related]
10. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.
Hoshino T; Naganuma A; Furusawa A; Suzuki Y; Hirai K; Sakamoto I; Ogawa T; Ogawa A; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Aug; 15(4):776-783. PubMed ID: 35585285
[TBL] [Abstract][Full Text] [Related]
11. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
[TBL] [Abstract][Full Text] [Related]
12. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.
Kondo T; Fujiwara K; Nakagawa M; Fujimoto K; Yumita S; Ishino T; Ogawa K; Iwanaga T; Koroki K; Kanzaki H; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Ogasawara S; Nakamoto S; Chiba T; Kato J; Kato N
Sci Rep; 2023 Jul; 13(1):11524. PubMed ID: 37460776
[TBL] [Abstract][Full Text] [Related]
13. Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
Hatanaka T; Naganuma A; Furusawa A; Tamura Y; Saito N; Suzuki Y; Hoshino T; Yata Y; Uraoka T; Kakizaki S
Oncology; 2023; 101(3):193-202. PubMed ID: 36649691
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review.
Sato S; Aoki T; Matsumoto T; Shiraki T; Mori S; Iso Y; Nemoto T; Onishi T; Iijima M; Ishida K
Clin J Gastroenterol; 2024 Apr; 17(2):292-299. PubMed ID: 38071671
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
Ishikawa T; Yamazaki S; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Anticancer Res; 2024 Jan; 44(1):361-368. PubMed ID: 38159993
[TBL] [Abstract][Full Text] [Related]
16. A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy.
Goto Y; Tajiri K; Tanaka S; Murayama A; Muraishi N; Hayashi Y; Yasuda I
Clin J Gastroenterol; 2023 Apr; 16(2):244-249. PubMed ID: 36625992
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
Cancer Med; 2022 Oct; 11(20):3796-3808. PubMed ID: 35441477
[TBL] [Abstract][Full Text] [Related]
18. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Yokohama K; Nishikawa H; Nishimura T; Shimada N; Kawata K; Kosaka H; Naganuma A; Yata Y; Ohama H; Kuroda H; Aoki T; Tanaka K; Tanaka T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M; Kumada T;
Hepatol Res; 2024 Apr; 54(4):382-391. PubMed ID: 37983642
[TBL] [Abstract][Full Text] [Related]
20. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
